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ABSTRACT
The hazard to public health from lead continues to be a matter of concern. It is one of the most serious environmental poisons among the toxic 
heavy metals all over the world. Lead poisoning is seen in all age groups, especially in adults working in lead-based industries. We report the case of 
a 28-year-old man working in an unorganized lead-based manufacturing unit admitted with the complaints of giddiness, excessive tiredness, pain 
in the upper abdomen, decreased appetite, excessive body pains, increased sweating, and oliguria. Investigations carried out during the admission 
showed hemoglobin levels of 8.5 g/dl and blood lead level (BLL) of 115 μg/dl. The patient was subjected to chelation therapy. After repeated course 
of chelation therapy, he has shown the signs of improvement. The paucity of a safe workplace and awareness among workers results in high BLLs. 
Therefore, education and awareness related to lead hazards is considered necessary.
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INTRODUCTION
Lead is a pervasive metal with unique properties such as softness, high 
malleability, ductility, low melting point, and resistance to corrosion 
which has been used by mankind for many years [1]. The hazard to 
public health from lead continues to be a matter of concern. It is one of 
the most serious environmental poisons among the toxic heavy metals all 
over the world. People are using lead for many years because of its wide 
variety of applications as building materials, pigments, pipes and in the 
manufacture of kitchen utensils, trays, and other decorative articleHuman 
exposure to lead is from innumerable sources, and the major sources 
are contaminated air, food, dust, soil, and water; use of certain products 
containing lead such as lead-soldered cans, traditional practices such as 
herbal or folk remedies, lead bullets, jewelry, cosmetics, artisan ceramics, 
environmental emissions containing lead production; through occupations 
such as motor vehicle assembling, lead smelting, refining, alloying and 
casting, battery manufacturing and recycling, lead paint, jewelry, welding 
and pottery [4,5]. Lead poisoning is seen in all age groups, especially in 
adults working in lead-based industries are benighted of the ill effects 
of lead. The mainstay of treatment for lead toxicity is chelation therapy 
with oral succimer, penicillamine or parenteral dimercaprol edetate, and 
calcium disodium edetate [6]. Here, we report a case of 28-year-old man 
who was diagnosed with chronic lead poisoning.
CASE REPORT
A 28-year-old male admitted to the hospital with complaints of 
giddiness, excessive tiredness, pain in the upper abdomen, decreased 
appetite, excessive body pains, increased sweating, and oliguria. He 
is a smoker, occasional alcoholic, married, and no significant allergic 
history was found. Occupational history revealed that he had been 
working in an unorganized lead-based manufacturing unit for 4 years. 
On examination, his pulse rate was 82/minutes and blood pressure 
was 124/60 mmHg. Results of various laboratory investigations were 
normal except hemoglobin - 8.5 g/dl (normal range: 14-16 g/dl), 
blood urea-62 mg/dl (15-45 mg/dl), serum creatinine - 1.7 mg/dl 
(0.6-1.2 mg/dl), zinc protoporphyrin (ZPP) - 126 μg/dl (up to 40 μg/dl), 
and blood lead level (BLL) - 115 μg/dl (acceptable range 10 μg/dl). 
Peripheral smear revealed microcytic hypochromic anemia. On the basis 
of these findings, the diagnosis of chronic lead poisoning was made. 
The patient was advised to change his occupation and treated with 
three courses of chelation therapy using the chelator D-penicillamine 
(25-35 mg/kg/days) in divided doses along with supplemental 
measures. After repeated course of chelation therapy, he showed 
some signs of improvement. He responded with an improvement in 
hemoglobin to 12.8 g/dl. The blood level of lead and ZPP before and 
after chelation therapy was shown in Table 1.
DICUSSION
In the present study, the patient was unaware of the ill effects of 
lead and was handling lead without taking any precautions even 
though they have provided protective equipment, resulted in chronic 
lead poisoning. Elevation of serum creatinine and blood urea level 
indicated kidney damage as a result of chronic lead exposure. Several 
studies explained various effects on the body based on serum lead 
level which includes teratogenicity when the maternal BLLs are 
at a concentration of 10-15 µg/dl, reduced prostate and seminal 
function at BLLs of 40-50 µg/dl, neurological symptoms, anemia at a 
concentration of 40-70 and 50-80 µg/dl, respectively, brain and renal 
damage at serum concentration of 100 µg/dl in adults and 80 µg/dl in 
pediatrics. Death due to lead poisoning is seen at serum concentration of 
125 µg/dl in pediatrics [7,8]. Lead in the body comprises 2% in the blood 
(t1/2=35 days) and 95% in bone and dentine (t1/2=20-30 years). Blood 
lead may remain elevated for years after cessation from long exposure, 
due to redistribution from bone. Blood lead concentration is the most 
widely used marker for inorganic lead exposure. ZPP concentration in 
blood usefully reflects lead exposure over the prior 3 months [9,10]. 
The toxic effects of lead are majorly due to higher affinity to thiol- and 
phosphate-containing ligands thereby inhibiting biosynthesis of heme 
and affecting membrane permeability of major organs such as kidney, 
liver, and brain resulting in altered functioning and degradation 
of these tissues. Lead also acts by inhibiting aminolaevulinic acid 
dehydratase thereby blocking the conversion of aminolaevulinic acid to 
porphobilinogen which leads to elevated levels of aminolaevulinic acid 
results in decreased gamma-aminobutyric acid release [11]. The clinical 
manifestations of lead poisoning: Nervous system include headache, 
fatigue, ataxia, myalgia, seizures, hallucinations, loss of memory, mental 
retardation, encephalopathic syndrome; gastrointestinal system are 
nausea, vomiting, constipation, and metallic taste; reproductive system 
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include abnormal spermatogenesis, sterility in males, and miscarriage 
in pregnant women; hematopoietic system are anemia, elevation in 
protoporphyrin is usually observed; renal effects include glycosuria, 
proteinuria, nephropathy whereas systemic and renal hypertension is 
commonly observed cardiovascular manifestations. Other acute toxicity 
manifestations include limb, joint pain, and deposition of lead in teeth and 
bones on chronic exposure [12-14]. Although chelation therapy removes 
lead from the blood and soft tissues, on discontinuation of treatment, 
it is redistributed from the bony compartment to the blood [15]. This 
evidently suggests that the chronic lead exposure requires repeated 
courses of treatment. The patients undergoing chelation therapy require 
intensive monitoring throughout the treatment period and BLLs should 
be estimated at the end of each course, and the subsequent therapy 
should be based on this determination.
CONCLUSION
The paucity of a safe workplace and awareness among workers results in 
high BLLs. Therefore, education and awareness related to lead hazards is 
considered necessary. The regulatory bodies should make it mandatory 
to evaluate and create awareness among public as well as workers in 
lead-based industries about the ill effects of lead and should insist on 
regular health checkup to prevent adverse health effects. Furthermore, 
pharmacy professionals should assist in providing patient education, 
psychological support, and conducting campaign against lead hazards.
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Table 1: BLL and ZPP levels before and after chelation therapy
Parameters Before therapy After 1st course 
of therapy
After 2nd course 
of therapy
1 month after 
discontinuing therapy
After 3rd course 
of therapy
BLL (µg/dl) 126 65 52 61 45
ZPP (µg/dl) 115 59 48 63 55
ZPP: Zinc protoporphyrin, BLL: Blood lead level
